antimycotic agents
TRANSCRIPT
-
8/7/2019 Antimycotic Agents
1/25
4/18/2011 Group 4 1
ANTIMYCOTIC AGENTSAND THEIR PROPERTIES
BY
MAWULI ATIEMO
-
8/7/2019 Antimycotic Agents
2/25
4/18/2011 Group 4 2
INTRODUCTION
Mycosis is term forinfections caused by fungi
and the study of fungal infectionsis referred to
asmycology.
Antimycotics agents are drugs used to treatfungal infections.
Fungi are free-living micro-organisms that
exist asyeasts (single-cell, round fungi),molds (multicellular filamentous fungi), or a
combination of the two (so-called dimorphic
fungi)
-
8/7/2019 Antimycotic Agents
3/25
4/18/2011 Group 4 3
Maingroups of fungi
Yeast e.g. Cryptococcus neoformans
Yeast like fungi that produces a sture
resembling a mycelium e.g. Candidaalbicans
Filamentous fungi (Molds) with true
mycelium e.g. Aspergillus fumigatus
Dimorphic fungi e.g. Histoplasma
capsulatum
-
8/7/2019 Antimycotic Agents
4/25
4/18/2011 Group 4 4
CHARACTERISTICS
eukaryotic -
Saprophytic - feed on dead organisms
Rigid cell walls containingchitin as well aspolysaccharides
Cell membrane composed ofergosterol (Cholesterol formammalians)
Phylogenetic similarity with humans - homologousmetabolic pathways for energy production, proteinsynthesis and cell division.
Most fungi have detoxification system that modifiesantifungal agents.
Greater difficulty in developingselective antifungalagents thanin developingselective antibacterial agents
-
8/7/2019 Antimycotic Agents
5/25
4/18/2011 Group 4 5
SUSCEPTIBILITY
surgical and intensive care unit (ICU) patients
patients with prostheses
patients with compromised immune defenses
e.g. HIV immunosuppressive therapy
the extensive use of broad-spectrum antibioticsand steroids
the wider use of long-term intravenous
cancer chemotherapy
the successes of organ transplantation
Diabetics and pregnant women etc.
-
8/7/2019 Antimycotic Agents
6/25
4/18/2011 Group 4 6
Diagnosis
Traditional methodsculture-base method
direct examination ofspecimens under lightmicroscopy
focus of modern mycologypolymerase chain reaction (PCR),
western blot
antigen detection (serology)
identification of fungal metabolites
Because these techniques are still investigational, they must beperformed in parallel with traditional culture-base method.
-
8/7/2019 Antimycotic Agents
7/25
-
8/7/2019 Antimycotic Agents
8/25
4/18/2011 Group 4 8
Class of Antimycotic Agents
Characteristics ofideal Antimycotic
Agent:
1. broad spectrum of action2. low drug toxicity
3. multiple routes of administration
4. excellent penetrationinto the CSF,
urine and bone
-
8/7/2019 Antimycotic Agents
9/25
4/18/2011 Group 4 9
Cellular Targets of Antimycotic Agents
-
8/7/2019 Antimycotic Agents
10/25
4/18/2011 Group 4 10
Cellular Targets ofAntimycotic Agents
Currently antifungal agents act on distinctmolecular targets.
1. Flucytosine inhibits fungal DNA synthesis
2. Griseofulvin (Penicillium griseofulvum)inhibits
fungal mitosis by disrupting mitotic spindles.3. Allylamines, Benzylamines, imidazoles andtriazolesinhibit the ergosterol synthesispathway in the ER.
4. Polyenes (Amphotericin B) bind to ergosterol
in the fungal membrane and thereby disruptplasma membrane integrity.
5. Echinocandins (caspofungin, micafungin &anidulafungin) inhibit fungal cell wall synthesis.
-
8/7/2019 Antimycotic Agents
11/25
4/18/2011 Group 4 11
Inhibitors ofFungal Nucleic acid
synthesis: Flucytosine
Mechanism
Flucytosine enters the fungal cell via atransmembrane cytosine permease.
Inside the cell, cytosine deaminase convertsflucytosine to 5-fluorouracil (5 FU), which issubsequently converted to 5 fluorodeoxyuridylicacid monophosphate (5 FdUMP).
5 FdUMPinhibits thymidylate synthase andthereby blocks the conversion of deoxythymidylate(dTMP).
In the absence of dTMP, DNA synthesisisinhibited.
-
8/7/2019 Antimycotic Agents
12/25
4/18/2011 Group 4 12
Flucytosine cont.
Clinical App- Limited to candidiasis,cryptococcosis and chromomycosis
Pkinetics Easily penetrate CNS. Renalexcretion
Contraindication Pregnancy
Adverse Effects - bone narrow suppression(leading to leukopenia and thrombocytopenia),GIT disturbance( nausea, vomiting, diarrhea),cardiotoxicity and hepatic dysfunction
Coadministration with Amphotericine B reducesthe likelihood of the emergence of resistance toFlucytosine
-
8/7/2019 Antimycotic Agents
13/25
4/18/2011 Group 4 13
Inhibitors of fungal mitosis: Griseofulvin Mechanism - Binds to tubulin and a microtubule
associated protein, thereby disrupting assembly ofthe mitotic spindle thereby disrupting cell division.
Pkinetics -
Absorption Enhanced if drugis taken with fattymeal. Nearly complete but varies with particlesize.
Distribution about 84% bound to plasma
proteins Metabolism Metabolized in the liver .
Elimination t1/2is 9-24hrs
Excretion urine (1%), faeces(36%), sweat
-
8/7/2019 Antimycotic Agents
14/25
4/18/2011 Group 4 14
Cont. Clinical App.- Fungal infection of the skin, hair, ornail
due to Trichophyton, Microsporum, or Epidermophyton.Not effective against yeast & dimorphic fungi.
Contra indications: severe liver ds, lupuserythematosus, pregnancy
Adverse effects 1.CNS (headache, lethargy, vertigo,blurred vision)
2. GIT (dry mouth, flatulence, oral candidiasis)3.Haematological (leukopenia, neutropenia)4.Angioedema, 5. exfoliative dermatitis.
Interactions FulcininducesC. P450 enzyems1. increases metabolism of anticoagulants e.g warfarin,
2. reduces the efficacy of oral contraceptives
-
8/7/2019 Antimycotic Agents
15/25
4/18/2011 Group 4 15
Inhibitors of 14 Sterol Demethylase:
Imidazoles & Triazoles Mechanism - Inhibit ultimate conversion of lanosterol
to ergosterol by inhibiting 14 sterol demethylase;
the resulting decrease in ergosterol synthesis and
accumulation of 14 methyl sterols disrupt thetightly packed acyl chains of the phospholipidsin the
fungal membrane.
Include:1. Imidazoles Ketoconazole, Clotrimazole,
Miconazole
2. Triazoles Fluconazole, Itraconazole
-
8/7/2019 Antimycotic Agents
16/25
4/18/2011 Group 4 16
Ketoconazole Indications Systemic mycoses, serious chronic resistant
mucocutaneous candidiasis, chronic resistant vaginal candidiasis, resistant
dermatophyte inf. ofskin or fingernails, prophylaxis of mycosesin
immunosuppressed patients.
Pkinetics
Absorption oral bioavailability is 75%
Distribution 90% bound to plasma protein Metabolism in the liver
Elimination t1/2 - biphasic 2hrs & terminal t1/2 of 8hrs.
GIT absorption of oral Ketoconazole depends on conversion of the drug to
a salt in the acidic envt of the stomach.
Excretion faeces as metabolites & unchanged drug, urine 13%Contra indication Achlorhydria patients, patients on bicarbonates,
antacids, H2- blockers, orPPI, pregnancy
Interactions Isoniazid, Rifampicin s plasma conc.
Anticoagulant effect enhanced by Ketoconazole.
s plasma conc. Antidiabetics ( sulfonylureas).
-
8/7/2019 Antimycotic Agents
17/25
4/18/2011 Group 4 17
Fluconazole Most widely used antifungal. Hydrophilic azole available in both oral or
i.v. preps
Indication vaginal candidiasis, systemic candidiasis, cryptococcalmeningitis, prophylaxis of fungal inf. inimmunocompromised patients
following cytotoxic chemotherapy or radiotherapy.
Pkinetics
Absorption- Well absorbed p.o. Bioavailability isnearly 100% from oral
route but . Not affected by gastric PH
unlike Ketoconazole. Distribution Concentrationsin the CSF 50 90% of plasma conc.
Protein bindingis only about 12%.
Metabolism Partially in the liver. Elimination t1/2 of 30hrs
Excretion about 61-88% unchanged in urine and 11% as metabolites.
Contra indication- pregnancy, hypersensitivity to Fluconazole Adverse effect GIT (nausea, vomiting, abdominal pain), Hepatic
disorders, Steven- Johnsonsyndrome, CNS ( headache, seizures)
Interactions-s levels of Amitriptyline, Cyclosporine, Phenytoin, Warfarin
s levels & effect ofFluconazole by Carbamazipine,
Phenobarbital, Isoniazid.
-
8/7/2019 Antimycotic Agents
18/25
4/18/2011 Group 4 18
Inhibitors of Ergosterol synthesis pathway
( Inhibitors of Squalene Epoxidase)
Mechanism - Inhibit conversion ofsqualene tolanosterol by inhibitingsqualene epoxidase.
E.g. - Allylamines (terbinafine & naftifine) &Benzylamines ( butenafine
TERBINAFINE Indications- Dermatophyte infs. ofskin & nails,
ringworm inf. (Tinea pedis, T. cruris & T. corporis.)
Terbinafine available in both oral & topical preps.
Topically Allylamines and Benzylamines are moreeffective than topical azoles against commonDermatophyte, esp. Tinea pedis. They are however,less effective than topical azoles against Candidaskininfections.
-
8/7/2019 Antimycotic Agents
19/25
4/18/2011 Group 4 19
Terbinafine cont.
PkineticsAbsorption - 40% bioavailability after oral admin.
Distribution- 99% bound to plasma proteins.
Metabolism- 1st pass metabolism in liver
Elimination t1/2 approx. 22 - 26hrs
Excretion up to 70%in urine and 20%in faeces
Contra-indication: renal/hepatic failure, pregnancy
Adverse effect hepatotoxicity, Steven-Johnsonsyndrome,neutropenia
Interactions- 1. Cimetidine + Terbinafine = s plasma levels
2. Rifampicin + Terbinafine = s plasma levels
-
8/7/2019 Antimycotic Agents
20/25
4/18/2011 Group 4 20
Inhibitors of fungal membrane stability: Polyenes
Mechanism - Bind to ergosterol and form pores that alter fungalmembrane permeability and stability.
E.g. Amphotericin B & Nystatin- natural pdts from streptomycesspps
Amphotericin B used to be most effective drug forsystemic mycoses.
Pkinetics Highly insoluble. Supplied as buffered deoxycholatecolloidal suspension. Poorly absorbed 4m GIT. Admini.v preferred.
90% bound to tissuessites, 10% bound to plasma protein
Distribution- CSF, vitreous humour and amniotic fluid.
Adverse effect- Toxicity of Ampho B limitsit clinical use. 3 main effects-1.systemic rxns (hypotension, fever and chills)
2. renal toxicity (nephrotoxicity)
3. haematological effects ( decreased prdxn of erythropoietin)
Interactions- Nephrotoxic drugs like aminoglycosides andcyclosporine s plasma levels
Amphotericin B in liposomes or lipid formulations reducesnephrotoxicity.(prevent exposure to proximal tubule)
-
8/7/2019 Antimycotic Agents
21/25
4/18/2011 Group 4 21
Nystatin
Indication- topical candidiasisinvolving the
skin, vaginal mucosa and oral mucosa Pkinetics
Absorption Insignificant orally. Not absorbed
systemically after topical admin Excretion as unchanged drugin faeces.
Adverse effect- Rashes, oral irritation,
nausea, vomiting, diarrhoea at high doses.
-
8/7/2019 Antimycotic Agents
22/25
4/18/2011 Group 4 22
Inhibitors of fungal wall synthesis:
EchinocandinsMechanism - Noncompetitively inhibit synthesis of (1,3)
D glucans (cell wall chitins), which leads to disruption ofcell wall integrity.
They include caspofungin, micafungin and anidulafungin.
Indications- invitro and invivo antifungal activity againstCandida andAspergillus spps.
All 3 Echinocandins are fungicidal against Candida spps. ( C.glabrata & C. krusei) and fungistatic againstAspergillusspps.
Available only in parenteral forms due to poor bioavailabilityafter p.o admin
Adverse effect headache, fever, pruritus, GIT disturbancesthrombophlebitis
Interaction - cyclosporine + caspofungins plasma conc.and elevate liver fxn enzymes
-
8/7/2019 Antimycotic Agents
23/25
4/18/2011 Group 4 23
EXAMPLES OF SOMEANTIMYCOTIC AGENTS
A Griseofulvin
B Nystatin
C Amphotericin(R=H) and its methyl
ester (R=CH3)
-
8/7/2019 Antimycotic Agents
24/25
4/18/2011 Group 4 24
REFERENCES
1. Galbraith, A., Bullock, S. et al. Fundamentals ofPharmacology (a text book forNurses & Health Professionals), 1st edition(1997). Pearson Education Limited, England. Pages 673 - 676
2. Golan, D.G, Tashjian, A. H. Jnr, et al. Principles ofPharmacology, the Pathophysiologic Basis ofDrug Therapy, 2nd
edition (2008). Lippincott Williams & Wilkins, U.S.A. Pages 619 630
3. Hugo, W.B, Russell A.D, Pharmaceutical Microbiology 6th edition(Blackwell, 1998)Page 121
4. Medicine InformationHandbook, 2nd edition (2009), NationalDrug Information Resource Centre, Accra. Pages 155-162
5. Olson, J. Clinical Pharmacology made simple, 2nd edition (1991)
MedMaster Inc. U.S.A pg118 1196. Katzung, B.G., Basic and Clinical Pharmacology, 7th Edition
(1998). Appleton & Lange, Stanford, U.K . Page 780
7. Rang, H.P, Dale, M.M et al. Rang and DalesPharmacology, 6th
Edition (2007). Churchill Livingstone Elsevier. Pages 692-693
-
8/7/2019 Antimycotic Agents
25/25
4/18/2011 Group 4 25
THANK YOU
MERCI